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METHODOLOGY
Transfection with thymidine kinase 
permits bromodeoxyuridine labelling of DNA 
replication in the human malaria parasite 
Plasmodium falciparum
Catherine J. Merrick*
Abstract 
Background: Plasmodium falciparum, the causative agent of severe human malaria, is an early-diverging protozoan 
whose lifecycle has many unusual features, including its modes of replication. Research on the Plasmodium cell cycle, 
which occurs primarily via schizogony instead of canonical binary fission, has been hampered by a lack of tools and 
markers that can be transferred from cell cycle studies in model organisms. A common tool used to study DNA repli-
cation and the cell cycle in human cells is the labelling of newly-replicated DNA with the modified nucleotide bromo-
deoxyuridine (BrdU), followed by immunofluorescent detection. Plasmodium parasites, however, do not incorporate 
BrdU because they rely only on de novo synthesis of pyrimidines and do not salvage thymidine analogues like BrdU for 
conversion into nucleotides.
Methods: Analysis of biochemical pathways in Plasmodium indicated that the absence of the enzyme thymidine 
kinase (TK) may be the only impediment to BrdU incorporation in this organism. A TK gene from Herpes simplex was, 
therefore, introduced into the Plasmodium falciparum 3D7 strain and the effect on BrdU labelling was assessed by 
enzyme-linked immunosorbent assay and immunofluorescence microscopy.
Results: Introduction of a TK gene produces parasites that can indeed incorporate BrdU. This forms a sensitive indica-
tor of DNA replication, which can be detected by both quantitative and qualitative assays on either a population level 
or a single-cell level. Plasmodium falciparum, when expressing TK, becomes unusually sensitive to BrdU toxicity.
Conclusions: BrdU labelling represents a significant new tool for investigating DNA replication and the cell cycle in 
Plasmodium.
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Background
Human malaria caused by Plasmodium parasites gives 
rise to widespread morbidity and more than half a mil-
lion deaths each year [1]. New methods of malaria con-
trol, including novel anti-malarial drugs, are urgently 
needed and their development could be informed by a 
better understanding of the basic biology of the causative 
parasite: an unusual protozoan with a complex lifecycle. 
Plasmodium lives primarily intracellularly in its two 
hosts, the human (or other vertebrate host) and the mos-
quito, where it undergoes distinct modes of both sexual 
and asexual replication. Modes of cell division differ at 
the different lifecycle stages, but Plasmodium does not 
divide by binary fission, in fundamental contrast to the 
normal cell cycle of both its hosts. Instead, it divides pri-
marily by schizogony: this is the division mode for all the 
lifecycle phases that occur in the human host, both inside 
hepatocytes and inside erythrocytes. In schizogony, mul-
tiple rounds of DNA replication occur inside a single cell 
prior to cytokinesis. This complicates the interpretation 
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of the Plasmodium cell cycle in terms of canonical 
phases: gap 1 (G1), DNA synthesis (S), gap 2 (G2) and 
mitosis (M) [2–4]. Like any difference between the basic 
biology of host and parasite, schizogony presents a pos-
sible drug target. However, many aspects of the Plasmo-
dium cell cycle are poorly understood, in stark contrast 
with the extensively studied conventional eukaryotic cell 
cycle.
Research on this very basic aspect of Plasmodium biol-
ogy has been hampered by a lack of tools and markers 
that can be transferred directly from cell cycle studies 
in model organisms. For example, the cyclins and cyclin 
dependent kinases (CDKs) that are central regulators of 
cell cycle phases in all eukaryotes from yeast to human 
remain relatively poorly characterized in Plasmodium 
[5, 6]. Many chemical synchronizing agents do not work 
well on blood-stage parasites [7, 8], and flow cytometric 
monitoring of S-phase via cellular DNA content is com-
plicated by multiple asynchronous rounds of replication 
within each schizont. As a result, determining exactly 
what phase of the cell cycle a parasite is in, or when it 
starts and finishes S-phase, is largely limited to assess-
ing the morphology of the parasite by microscopy, as it 
develops from a pre-replicative ring stage into a replica-
tive trophozoite stage and then into a schizont stage, in 
which individual nuclei become visible inside the parent 
cell.
The incorporation of BrdU into actively-replicating 
DNA, followed by immunofluorescent detection with 
anti-BrdU antibodies, has long been a workhorse assay 
in mammalian cells, detecting cells in S-phase swiftly 
and sensitively. In fact, in the large nuclei of mammalian 
cells, distinct patterns of replication foci can be labelled 
at different stages of S-phase, allow the finer distinction 
of cells that are in early, mid or late S-phase [9].
Attempts were made more than two decades ago to 
adapt the BrdU labelling technique for Plasmodium 
(particularly because at this time, quantitative monitor-
ing of parasite replication otherwise required the labo-
rious incorporation of tritiated hypoxanthine, followed 
by scintillation counting). In 1988, an initial report was 
published on BrdU incorporation into Plasmodium, 
showing positive results with an enzyme-linked immuno-
sorbent assay (ELISA) [10]. Two further reports on this 
have also appeared in later years [11, 12]. By contrast, 
it has also been reported that Plasmodium parasites do 
not incorporate BrdU and that the absorbance of light 
by haemozoin, which accumulates inside schizonts, can 
be taken for bona fide labelling when measured only by 
ELISA [13]. Plasmodium is well known to rely on de novo 
synthesis of pyrimidines and does not therefore salvage 
thymidine analogues like BrdU for conversion into nucle-
otides [14–18].
The intra-erythrocytic parasite expresses a combina-
tion of membrane channels that should allow BrdU to 
cross all three membranes enclosing the parasite: the 
erythrocyte membrane, the parasitophorous vacuole 
membrane and the parasite plasma membrane [19–23]. 
There is also a tubulovesicular network that can bring 
small metabolites into close proximity with the parasite 
plasma membrane [24, 25]. Therefore, the only impedi-
ment to BrdU incorporation in Plasmodium species may 
be biochemical: the absence of the enzyme thymidine 
kinase (TK), which converts thymidine, and also its ana-
logs such as BrdU, from a deoxynucleoside into a deoxy-
nucleotide which can subsequently be incorporated into 
DNA. This same problem has been overcome in Sac-
charomyces cerevisiae by expressing a viral TK transgene 
[26]. With the advent of molecular genetics in malaria 
parasites, this is now similarly possible in P. falciparum, 
in which TK from Herpes simplex virus has been used as 
a negative selectable marker, making the parasites sensi-
tive to pro-drug nucleoside analogues such as ganciclovir 
[27].
This report shows that TK-expressing parasites can 
indeed be labelled with BrdU. Labelling can be detected 
by ELISA and also by immunofluorescence microscopy 
in single cells: evidence that was never shown in prior 
reports of BrdU labelling in wildtype parasites. In par-
allel assays, wildtype parasites remain unlabelled, just 
as reported in 1991 by Janse et al. [13]. At a population 
level, BrdU labelling measured by ELISA is a much more 
sensitive indicator of DNA replication than the stand-
ard malaria SYBR Green I fluorescence (MSF) assay 
[28]. Interestingly, TK-expressing parasites are much 
more sensitive to BrdU toxicity than mammalian cells. 
Nevertheless, BrdU labelling, when used in short-term 
endpoint assays, will represent a significant new tool for 
investigating DNA replication and the cell cycle in this 
unusual and medically-important parasite.
Methods
Parasites and parasite culture
Plasmodium falciparum 3D7 parasites were obtained 
from MR4 (mr4.org). Parasites were cultured in human 
O+ erythrocytes at 4 % haematocrit in RPMI 1640 sup-
plemented with 0.25  % albumax (Invitrogen), 5  % 
heat-inactivated human serum and 0.25 % sodium bicar-
bonate, using standard procedures [29]. Synchronized 
ring-stage parasites were produced by treatment with 5 % 
sorbitol [30], or by Percoll separation of schizont stages, 
followed by re-invasion into fresh erythrocytes [31].
Generation and characterization of TK‑expressing parasites
All transgenic parasites carried versions of the pHTK 
double-selectable gene-targeting plasmid ([27], available 
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from MR4), containing various different gene-targeting 
sequences cloned from the 3D7 genome, then trans-
fected into 3D7 parasites using standard procedures [32]. 
Southern blotting using the AlkPhos Direct Labelling and 
Detection system (GE Healthcare) was used to confirm 
that the parasite lines ‘+TK’ and ‘+TK(B)’ were carry-
ing the pHTK plasmid episomally, and that ‘+TK(int)’ 
was carrying a genome-integrated copy. Plasmid copy 
number in each +TK parasite line was determined by 
quantitative PCR using a StepOne Plus machine (Applied 
Biosystems) and the SensiFAST SYBR Hi-ROX kit (Bio-
line), on genomic DNA extracted from each parasite line 
via the QIAamp DNA blood mini kit (Qiagen). Primers 
for the TK gene, used at a final concentration of 125 nM, 
were: AGA AAA TGC CCA CGC TAC TG (forward) 
and CTC GAC CAG GGT GAG ATA TC (reverse). 
Primers for two single-copy housekeeping genes used 
as controls, PF3D7_0717700 (seryl-tRNA synthetase) 
and PF3D7_1246200 (actin), are previously described 
[33]. Cycling conditions were 50  °C 2 min, 95  °C 3 min, 
40cycles of 95 °C 15 s, 54 °C 40 s, 60 °C 1 min. The Rela-
tive Copy Number (RCN) of the TK gene was calculated 
as 2ΔCt, where ΔCt was relative to the average Ct of the 
two control genes. All PCR reactions were carried out in 
triplicate.
Malaria SYBR Green I fluorescence (MSF) assay
The BrdU (Sigma) used in all assays was dissolved in 
water as a 50 mM stock, aliquoted, frozen at −20 °C and 
thawed as required for dilution into culture medium. 
MSF assays for parasite growth were carried out essen-
tially as previously described [28], plating synchronized 
trophozoite-stage parasites at 0.5  % parasitaemia and 
2 % haematocrit in a 96-well format containing threefold 
serial dilutions of BrdU and then incubating for 48 h. In 
BrdU pulse assays, aliquots of parasite culture were incu-
bated in BrdU for the required period, then washed twice 
in fresh culture medium before plating. When ring-stage 
parasites were used in pulse assays, a sorbitol treatment 
(as for synchronization) was also used prior to the two 
washes, to eliminate any parasites that had progressed 
to trophozoite stage during the pulse-label: this ensured 
that only parasites exposed as rings were subsequently 
plated.
To read these assays, the resultant cultures were mixed 
with MSF lysis buffer and SYBR Green I fluorescence was 
measured using the GloMax multidetection system (Pro-
mega). Percentage parasite growth was calculated relative 
to the fluorescence readouts from the control culture, 
incubated without BrdU (100 % growth), and the culture 
incubated with the maximum concentration of BrdU (0 % 
growth). All assays were carried out in technical triplicate 
and representative datasets are presented from at least 
2 biological replicates. GraphPad Prism v.6.0 (GraphPad 
software Inc.) was used to plot growth inhibition curves 
via non-linear regression fitting, and thus to calculate 
50 % inhibitory concentration (IC50) values.
3‑(4,5‑dimethylthiazol‑2‑yl)‑5‑ 
(3‑carboxymethoxyphenyl)‑ 
2‑(4‑sulfophenyl)‑2H‑tetrazolium (MTS) assay
The MTS assay for viability of human cells was carried 
out using the MCF-7 breast cancer cell line, cultured in 
Eagle’s MEM. Trypsinized cells were plated in 96-well 
format at 2  ×  104 cells/well, allowed to attach for 3  h, 
then exposed to fivefold serial dilutions of BrdU for 
approximately 1 cell cycle (40  h), as per the MSF assay 
on parasites. The assay was read using the CellTiter 96 
Aqueous One Solution Cell Proliferation kit (Promega) in 
the GloMax multidetection system (Promega).
Parasite life‑cycle assay
Early ring-stage parasites, synchronized using Percoll, 
were exposed to 1  mM, 100  nM or 0 BrdU and their 
development was followed by blood smears, stained 
using the Hemacolor staining kit (Merck Millipore), at 
8  h intervals over the subsequent cell cycle. 100 para-
sites were classified for their developmental stage at each 
timepoint.
ELISA
Parasites were prepared for ELISA by releasing from 
erythrocytes using 0.15 % saponin/PBS, washing and re-
suspending in PBS, then plating in triplicate in 96-well 
format at either 2 × 105 or 1 × 106 parasites/well. Plates 
were allowed to air-dry, fixed for 5 min in 4 % formalde-
hyde/PBS and for 2 min in 50/50 methanol/acetone, then 
washed 3 times in PBS and blocked for 1 h in 1 % BSA/
PBS. All wells were treated for 3 h at 37  °C with mouse 
monoclonal anti-BrdU antibody BU-1 plus nuclease 
(Amersham, kit RPN202), washed three times in PBS, 
then treated for 1  h with anti-mouse HRP-conjugated 
secondary antibody (Dako) diluted 1:5000 in BSA/PBS. 
After three further washes in PBS, assays were developed 
using the Single-Component TMB Peroxidase EIA Sub-
strate Kit (BioRad), stopped with 0.6  N sulphuric acid 
and then read using the GloMax multidetection system 
(Promega). In parallel with the plating of parasites for 
ELISA, aliquots of the same suspension of parasites were 
mixed with MSF lysis buffer for an MSF-type assay, to 
confirm equal loading of parasite genomes across ELISA 
plates. All assays were carried out in triplicate.
Immunofluorescence
Parasites were prepared for immunofluorescence as air-
dried blood smears, fixed for 5 min in 4 % formaldehyde/
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PBS, then for 2  min in 50/50 methanol/acetone, then 
washed 3 times in PBS and blocked for 30  min in 1  % 
BSA/PBS. Slides were treated for 1 h with mouse mono-
clonal anti-BrdU antibody BU-1 plus nuclease (Amer-
sham, kit RPN202), washed three times in 1  % BSA/
PBS, treated for 1  h with anti-mouse Cy3-conjugated 
secondary antibody (Stratech Scientific) diluted 1:5000 
in BSA/PBS, then washed again three times with BSA/
PBS. 2  mg  ml−1 4′,6-diamidino-2-phenylindole (DAPI) 
was included in the second wash. Slides were mounted 
in 50/50 PBS/glycerol and examined using a Zeiss Axio 
Scope A1.
Results
Expression of thymidine kinase allows P. falciparum 
parasites to incorporate BrdU into genomic DNA
Biochemical pathways in P. falciparum have been exten-
sively characterized by homology searches within the 
sequenced genome and/or experimentally [34]. Analy-
sis of these pathways shows that the genome does not 
encode a TK enzyme, but does encode all the required 
enzymes for downstream conversion of nucleosides into 
nucleotides (Fig.  1a). Therefore, the only impediment 
to BrdU incorporation at the biochemical level should 
be the lack of a TK enzyme, since intra-erythrocytic 
parasites express a combination of channels that should 
allow nucleoside analogs like BrdU to enter the parasite 
(Fig. 1b).
A TK enzyme was, therefore, expressed in P. falciparum 
parasites by transfecting the standard laboratory strain, 
3D7, with the pHTK plasmid [27]. This plasmid carries 
the human dihydrofolate reductase (hDHFR) gene as a 
positive selectable marker and a Herpes simplex TK gene 
as a negative selectable marker to facilitate the generation 
of genetic knockouts by double homologous recombina-
tion. A parasite line carrying this plasmid as an episome 
(‘+TK’) was able to incorporate BrdU into actively repli-
cating trophozoite parasites, as demonstrated using both 
immunofluorescence and ELISA (Fig.  2a, b). Wildtype 
3D7 parasites exposed to BrdU in parallel did not show 
detectable levels of labelling, even at very high exposures 
of up to 1 mM for several hours (Fig. 2a, b), thus showing 
that the TK transgene was absolutely required for BrdU 
to be converted into a nucleotide and incorporated into 
genomic DNA.
BrdU is a more sensitive indicator of DNA replication 
than SYBR Green I DNA dye
BrdU labelling allows newly-replicated DNA to be distin-
guished from existing DNA, which is not possible with 
standard DNA-intercalating dyes such as 4′,6-diamidino-
2-phenylindole (DAPI) or SYBR Green I. In addition, 
BrdU labelling offers increased sensitivity compared to 
SYBR Green I, which is the DNA dye used in the stand-
ard MSF assay for parasite growth [28]. The MSF assay 
measures the increase in DNA content as a population 
of parasites progresses through at least one replicative 
cycle, generating an average of 16–32 new genomes per 
parasite per cycle. The MSF assay gives a broadly quan-
titative measure of DNA content but it has a relatively 
low dynamic range and high signal-to-noise ratio [35]. To 
compare this with the sensitivity of BrdU labelling, +TK 
parasites at mid-trophozoite stage (~30–36 h post inva-
sion) were exposed to BrdU for 1–4 h. Four hours should 
Fig. 1 Schematic of nucleotide metabolism and transport pathways in P. falciparum. a Enzymes required for the metabolism of pyrimidine nucleo-
sides to nucleotides for incorporation into DNA. Plasmodium species lack thymidine kinase but contain all the other enzymes shown downstream. 
b Schematic showing the route by which modified nucleosides like BrdU could enter intra-erythrocytic parasites. RBC red blood cell, PfNT1 P. falcipa-
rum nucleoside transporter 1
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cover approximately one round of genome replication if a 
parasite produces 16–32 daughter parasites via 4–5 suc-
cessive genome replications during its 16–20 h trophozo-
ite stage [3]. DNA replication during a 4-h period was not 
reliably detectable by SYBR Green I in an MSF assay, but 
was clearly detectable by anti-BrdU ELISA (Fig. 2c, d).
Parasites expressing thymidine kinase become sensitive 
to BrdU toxicity
The BrdU labelling technique is primarily used in short-
term endpoint assays, but in mammalian cells it can 
also be used over several cell cycles, and even in  vivo, 
with BrdU being added to the drinking water of mice to 
monitor the turnover of cellular compartments such as 
haematopoietic and intestinal cells over weeks or months 
[36]. BrdU is thus considered to be a relatively non-toxic 
DNA label in mammalian cells, despite the fact that it 
was originally developed as an anti-cancer agent to dis-
rupt DNA synthesis, and has been tested—largely with-
out success—in clinical trials as a radio-sensitizing agent. 
In a single-celled parasite like Plasmodium, this sort of 
long-term assay is unlikely to be required, but the use-
fulness of BrdU labelling might nevertheless be limited 
if acutely toxic levels were required to label parasites. 
Therefore, the toxicity of BrdU on P. falciparum was 
tested in a standard MSF assay.
Wildtype 3D7 parasites were essentially insensitive to 
BrdU, even at very high exposures of up to 1 mM over a 
Fig. 2 TK-expressing P. falciparum can incorporate BrdU, which is a sensitive indicator of DNA replication. a ELISA on wild-type (WT) and +TK 
parasites (2 × 105 parasites/well) after exposure to 1 mM BrdU for 4 h at the trophozoite stage. Error bars show standard deviation of triplicate read-
ings; star indicates the only significantly differing dataset (One-way ANOVA, p < 0.0001). b Immunofluorescence assay on (WT) and +TK parasites 
exposed to 100 mM BrdU for 12 h at trophozoite stage. c SYBR Green I staining of +TK parasites after exposure to no BrdU (−) or to 100 mM BrdU 
(+) for 1, 2 or 4 h. Parasites were released from erythrocytes and suspended in PBS [as for the ELISA assay shown in (a)], then plated with MSF lysis 
buffer at 1 × 106 parasites/well. The increase in DNA content over 3 h is not detectable by this MSF-type assay. Error bars show standard deviation 
of triplicate readings. rfu, relative fluorescence units. d ELISA on the same +TK parasites as in (c), plated at 1x106 parasites/well after exposure to no 
BrdU (−) or to 100 mM BrdU (+) for 1, 2 or 4 h. Background signal, obtained from the same parasites incubated without BrdU, has been subtracted 
from all readings, and error bars show standard deviation of triplicate readings. Figure c confirms that approximately the same numbers of parasites 
were plated in all cases
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48-h growth cycle (Fig.  3a). By contrast, +TK parasites 
were surprisingly sensitive, with a 50 % growth-inhibitory 
concentration (IC50) below 100 nM (Fig. 3b). Two inde-
pendent parasite lines, carrying different versions of the 
TK plasmid at different average copy-numbers (Addi-
tional file 1A), were tested to ensure that the presence of 
the TK gene was consistently responsible for this effect. 
IC50 values of 79 and 90 nM were measured in the two 
independent lines, confirming that +TK parasites behave 
consistently and also that the TK gene copy number has 
no apparent effect on BrdU sensitivity.
Several precautions were taken to ensure that the tox-
icity of BrdU in +TK P. falciparum lines was not arte-
factual. Firstly, an analogous assay for cell viability was 
carried out on a human cell line, MCF-7, using the same 
BrdU stock, to ensure that it was not toxic to human 
cells. These cells, as expected, showed no acute death 
when exposed to up to 1  mM BrdU over one cell cycle 
(Additional file 1B). All assays, on both human and Plas-
modium cells, were incubated in the dark at all times to 
reduce the risk of DNA damage caused by photo-activa-
tion of BrdU in DNA, because this compound is known 
to be UV-sensitizing as well as radio-sensitizing [37]. 
Finally, assays were carried out in both the presence and 
absence of the positive-selection agent for the pHTK 
plasmid, WR99210. This drug inhibits the dihydrofolate 
reductase activity of the P. falciparum bifunctional 
dihydrofolate reductase-thymidylate synthase enzyme 
Fig. 3 TK-expressing parasites become sensitive to BrdU toxicity. a MSF assay on WT and two different TK-expressing parasite lines, +TK and 
+TK(B), over a BrdU range of 1–0.46 mM. Error bars show standard deviation of triplicate readings. b MSF assay on the same parasites as in (a), over a 
range of 5–2.3 nM BrdU. IC50 values were calculated with GraphPad Prism software, 95 % confidence intervals are given in parentheses
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(PfDHFR-TS), but does not affect the human DHFR 
enzyme [32]. Therefore, WR99210 selects for the main-
tenance of plasmids carrying the hDHFR gene, because 
maintaining dihydrofolate reductase activity is essential 
for parasite growth. Human DHFR is well-established 
to be a fully effective substitute for the P. falciparum 
enzyme [32] and parasite lines carrying such plasmids 
grow stably, without impairment, on WR99210 selec-
tion; nevertheless, it remained possible that interfering 
with this pathway in the presence of a non-natural bro-
minated base might somehow affect the toxicity of BrdU. 
Therefore, assays were carried out using a parasite line 
that carried the pTK plasmid stably integrated into the 
genome via a single homologous recombination event, to 
avoid rapid episome loss in the absence of drug selection. 
WR99210 was removed from the parasites in the growth 
cycle preceding the MSF assay, and no difference in the 
IC50 of BrdU was seen in the presence or absence of 
WR99210 (Additional file 1C).
BrdU causes schizont‑stage arrest in TK‑expressing  
parasites
The standard MSF assay used in Fig. 3 simply measures 
overall growth inhibition over a 48-h growth cycle from 
trophozoites to daughter trophozoites. To investigate the 
exact stage of the Plasmodium cell cycle at which BrdU 
toxicity becomes apparent, highly synchronized ring-
stage +TK parasites (Fig.  4a, 0–8  h) were treated with 
either 0, 100  nM (~IC50) or 1  mM (~IC95) BrdU and 
morphology was assessed at regular intervals over the 
subsequent growth cycle (Fig.  4a). Parasites appeared 
to develop normally through the pre-replicative ring 
stage and most of the trophozoite stage, although some 
trophozoites exposed to BrdU did begin to appear out-
side erythrocytes (where they presumably become invia-
ble). The majority of parasites, however, progressed to the 
late trophozoite or early schizont stage. BrdU-exposed 
parasites then generally failed to release merozoites and 
reinvade: in 1  mM BrdU, there was a complete lack of 
reinvasion and only arrested, burst or exoerythrocytic 
parasites remained by the time the control population 
had produced the next generation of rings. At 100  nM 
BrdU, reinvasion did occur, but only at 49 % of the con-
trol rate (consistent with this representing an approxi-
mately IC50 exposure). This pattern closely resembles the 
parasite killing effect of WR99210, which prevents the 
completion of DNA synthesis by disrupting the supply 
of nucleotide precursors. WR99210 similarly causes late-
stage parasites to swell, burst and fail to reinvade.
These observations are consistent with a specific toxic 
effect occurring in schizonts after BrdU has been incor-
porated into genomic DNA. If the ring stage, prior to the 
onset of DNA replication, is genuinely insensitive, then 
parasites exposed to a pulse of BrdU as rings might be 
expected to develop normally through the subsequent 
replicative stages. However, a 4-h pulse of BrdU applied 
in the ring stage still appeared to be toxic if parasites were 
then allowed to progress through the subsequent replica-
tive stage and attempt reinvasion (data not shown). This 
raised the question: does the presence of brominated 
nucleosides or nucleotides have another (morphologi-
cally undetectable) effect on the ring stage itself? Or does 
ring-stage exposure simply load BrdU into the nucleotide 
pools later used for DNA replication?
Parasites were exposed to 4-h pulses of BrdU as rings, 
then washed and either harvested immediately or as late 
trophozoites in the replicative stage following exposure. 
No BrdU was detectable by ELISA in the ring-stage para-
sites, but after progression through the trophozoite stage, 
the parasites did become labelled with BrdU almost as 
strongly as when exposed during the trophozoite stage 
itself (Fig.  4b). This does not exclude any specific effect 
of BrdU on the ring stage, but it does suggest that ring-
stage exposure to BrdU can indeed load the nucleotide 
pool that is later used by the trophozoite to replicate the 
genome during S-phase.
The unusual sensitivity of Plasmodium falciparum to BrdU 
does not preclude the use of BrdU as a short‑term labelling 
agent
For most assays exploring S-phase dynamics, BrdU 
labelling for a full 48-h growth cycle is not necessarily 
required, and Figs.  2b and 4a both show that parasites 
develop quite normally through to the latest stages of 
S-phase even when exposed to BrdU at levels above the 
48-h IC50. Nevertheless, if long labelling periods are 
required, BrdU can clearly be detected by ELISA in a 
parasite population exposed for 48 h to BrdU levels well 
below the IC50 (Fig. 5a). Labelling can also be detected 
after much shorter pulse-labels of trophozoite para-
sites (Fig. 5b): certainly as little as 1 h at 1 mM, or 2 h at 
100 nM. Short pulse labels are somewhat less toxic than 
continuous exposure for a whole 48  h: for example, the 
48-h IC50 following a 1-h pulse of BrdU was measured 
at 219 nM (Fig. 5c): three times higher than the IC50 for 
continuous exposure.
In conclusion, the BrdU labelling technique could 
prove useful for many experiments on DNA replication 
in P. falciparum, despite the unusually toxic effect of 
BrdU in this organism.
Discussion
The technique reported here will allow BrdU labelling of 
replicating DNA to be used in any Plasmodium parasite 
that is transfected with a TK gene. The technique is fun-
damentally different from the use of standard DNA dyes 
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to detect the genomic contents of parasites, because it 
can distinguish new DNA synthesized during any defined 
labelling period from pre-existing DNA.
While developing this technique, it became apparent 
that P. falciparum parasites expressing a TK transgene are 
unusually sensitive to BrdU toxicity. The reason for this is 
Fig. 4 BrdU causes schizont-stage arrest in TK-expressing parasites. a Developmental stages of +TK parasites assessed at 8 h intervals over a single 
growth cycle in the presence of 0, 100 nM or 1 mM BrdU. 100 parasites were counted at each timepoint. Photographs show representative parasite 
morphology at each stage: R ring, ET early trophozoite (parasite less than half the width of host cell), MT middle trophozoite (parasite more than 
half the width of, but not entirely filling, host cell), LT late trophozoite (parasite filling all or nearly all of host cell), ES early schizont (nuclear masses 
visible within parasite), LS late schizont (defined merozoites visible), P pyknotic (parasite stained as a dense shrunken intracellular dot without clear 
morphological features), O parasite outside erythrocyte, hpi hours post invasion. b ELISA on +TK parasites, plated at 1 × 106 parasites/well, after 
ring-stage exposure to 0, 0.41, 11 or 100 mM BrdU for 4 h. Parasites were either harvested immediately after washing out the BrdU, as rings, or cul-
tured until the late-trophozoite stage and then harvested for ELISA. Control (ctrl) parasites were cultured to the trophozoite stage before exposing 
to 100 mM BrdU for 4 h at this stage and then harvesting immediately. The background signal, obtained from parallel samples incubated without 
BrdU, has been subtracted from each set of readings. Error bars show standard deviation of triplicate readings
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unclear, but certainly has to do with the non-natural abil-
ity to metabolize BrdU into a nucleotide—and probably 
to incorporate it into genomic DNA during S-phase—
because parasites lacking the TK gene are entirely insen-
sitive. Notably, the toxic effect of high-level BrdU means 
that it could be as effective as ganciclovir in negative 
selection of TK-carrying genetic recombinants. This may 
be particularly advantageous if it reduces the ‘bystander 
effect’ seen with ganciclovir, in which neighbouring cells 
are killed via diffusion of toxic metabolites [27].
BrdU is not universally toxic in organisms that do not 
naturally possess TK activity: S. cerevisiae also lacks TK, 
but overexpression of a TK transgene allows this yeast 
to incorporate BrdU without overt toxicity [26]. Several 
unusual features of P. falciparum biology may account 
for its inability to survive well with BrdU-substituted 
DNA. This parasite has one of the most AT-rich genomes 
ever sequenced at 80.6  % [38], so the potential density 
of BrdU substitutions for thymidine bases is unusually 
high. However, similarly biased genomes do exist, nota-
bly in Dictyostelium discoideum (77.6  % A/T [39]), and 
although BrdU may inhibit the developmental cycle of 
this organism [40, 41], vegetative amoebal growth does 
not appear to be highly sensitive to BrdU. Indeed, an 
IC50 of 75  mg  ml−1 (0.24  mM) appears in one report 
[42], which is more than a thousand-fold higher than the 
IC50 for TK-expressing P. falciparum, and BrdU labelling 
experiments at very high exposures have been used in D. 
discoideum without reported toxicity [43].
A second possibility relates to the near-absence of CpG 
methylation in the P. falciparum genome (this modifica-
tion was long thought to be entirely absent [44]; it has 
Fig. 5 Toxicity does not preclude the use of BrdU as a short-term labelling agent in P. falciparum. a ELISA on +TK parasites, plated at 1 × 106 
parasites/well, after 48 h exposure to the three lowest concentrations of BrdU used in the MSF assay shown in Fig. 3b. Background signal, obtained 
from the sample incubated without BrdU, has been subtracted from all readings. Error bars show standard deviation of triplicate readings. A parallel 
MSF-type assay on the same parasites shows that DNA content is similar in all samples, confirming that within 48 h, severe growth inhibition has 
not occurred at these sub-IC50 exposures. b ELISA on +TK parasites (1 × 106 parasites/well), after pulses of BrdU from 15 min to 4 h, applied at the 
trophozoite stage. The background signal, obtained from parallel samples incubated without BrdU, has been subtracted from each set of readings. 
Error bars show standard deviation of triplicate readings. c MSF assay on +TK parasites after 1 or 2 h pulses of BrdU (5 mM to 2.3 nM) at trophozoite 
stage, followed by washing and growth in fresh medium for 48 h. Parasites were also kept in BrdU for the full 48 h, as in Fig. 3b, for comparison. Error 
bars show standard deviation of triplicate readings. IC50 values were calculated with GraphPad Prism software, 95 % confidence intervals are given 
in parentheses
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recently been detected, but at unusually low levels [45]). 
It may be that the parasite has a diminished ability to tol-
erate, replicate through or transcribe through modified 
pyrimidine bases, and therefore experiences replicative 
or transcriptional problems upon encountering bromi-
nated bases.
Thirdly, the unusual nature of schizogony may present 
a particularly severe problem for BrdU-substituted DNA, 
as suggested by the specific cell cycle arrest observed at 
the schizont stage. During schizogony, the parasite has 
the topologically challenging task of separating dozens 
of genomes into individual merozoites, without appar-
ent chromosome condensation, and BrdU-substituted 
genomes may disturb this process, particularly if they 
cause, or are recognized as, DNA damage. In human 
cells, BrdU does cause DNA damage and the activation of 
cell cycle checkpoints, albeit only at much higher levels. 
For example, a week-long exposure of one lung cancer 
cell line to 10 mM BrdU was reported to elicit features of 
a DNA damage response, cell cycle arrest, and eventually 
a senescence-like phenotype without cell death [46]. Lit-
tle is known about DNA damage checkpoints in Plasmo-
dium; in fact this is one very attractive area to which to 
apply this new technique.
The BrdU labelling technique will also allow the Plas-
modium cell cycle to be studied at unprecedented tem-
poral resolution. This is of considerable interest for 
characterizing the dynamics of intra-erythrocytic schiz-
ogony, and arguably even more so for examining the very 
rapid process of male gametogenesis [47] (objectives that 
we are now actively pursuing). In particular, the dynamics 
of successive replicative cycles during schizogony remain 
unexplored. This report has clearly showed that parasites 
can pre-load their nucleotide pools with BrdU during 
the ring stage and that this cannot be ‘washed out’, pre-
sumably because the cell, although permeable to nucleo-
sides, is not equally permeable to phosphorylated, and 
therefore charged, nucleotides. Thus, significant levels of 
BrdU labelling (and associated toxicity) are carried over 
into the replicative trophozoite stage. In human cells, 
nucleotide pools during S-phase can be rate-limiting for 
DNA replication: the pool increases sharply at S-phase 
entry and then throughout S-phase, resulting in replica-
tion rates increasing 2 to 3-fold across S-phase [48]. It 
is possible that nucleotide pools may begin to grow at 
an earlier point in the ring stage of the Plasmodium cell 
cycle, and it will be interesting to explore whether all the 
rounds of DNA replication occur at the same speed dur-
ing schizogony, or whether later genome replications are 
completed more rapidly.
DNA damage responses, including DNA repair, cell 
cycle checkpoints, and cell cycle arrest and recovery 
phenomena can also be studied using BrdU labelling. 
This is particularly pertinent in light of recent reports 
that parasites with tolerance to the anti-malarial drug 
artemisinin rely on cell cycle arrest and ‘dormancy’ to 
survive [49]. As yet, the full molecular mechanism for 
this remains uncharacterized. Beyond responses to anti-
malarial drugs, Plasmodium parasites may also have 
evolved replicative responses to many other stressors 
encountered in the human host. Dynamic host-parasite 
interactions remain understudied in human malaria 
parasites, yet they may have fast, flexible impacts upon 
virulence and disease pathogenesis. High parasitaemia, 
which is very likely to be partly determined by the rate of 
parasite growth and replication, is one of the best clinical 
predictors of severe malaria [50], so a better understand-
ing of the factors determining parasite growth and repli-
cation could have real medical relevance.
As demonstrated here, the unusual toxicity of BrdU in 
TK-expressing P. falciparum parasites does not preclude 
its potential usefulness as an experimental tool, but does 
highlight another interesting way in which Plasmodium 
biology differs from that of model eukaryotes. It will 
be interesting to examine whether other Plasmodium 
species are more or less sensitive to BrdU when TK is 
expressed, and whether this correlates with any particu-
lar factor in their biology. For example, the A/T bias in 
genome composition of the mouse malaria species P. 
berghei is similar to that of P. falciparum, whereas that 
of the simian and human-zoonotic species P. knowlesi 
(which is also genetically tractable) is only ~62 %.
Overall, this innovation will open up many new ave-
nues for studying the dynamics of DNA replication in the 
unusual cell cycle of Plasmodium. Since the biochemistry 
of all sequenced Plasmodium species appears to be simi-
lar, the potential is not limited to P. falciparum, but could 
be transferred to any Plasmodium model species amena-
ble to transfection. This includes mouse malaria which 
can be studied inside the mosquito and mammalian hosts 
more easily than the human parasite P. falciparum. Since 
in  vivo BrdU labelling in mice is already established, it 
would potentially be feasible to study all stages of the 
parasite’s lifecycle in these model systems. Finally, it will 
now be possible to explore the experimental potential of 
other thymidine analogs that will become viable tools 
in this new system, such as CldU, IdU and 5-ethynyl-2′-
deoxyuridine (EdU). EdU is detected via click-chemistry 
rather than antibodies, opening up a different suite of 
new experiments in Plasmodium biology.
Conclusion
The technique reported here will allow BrdU labelling of 
replicating DNA to be used in any Plasmodium parasite 
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transfected with a TK gene. This opens up many new ave-
nues for studying the dynamics of DNA replication in the 
unusual cell cycle of this parasite.
Abbreviations
BrdU: bromodeoxyuridine; TK: thymidine kinase; CDKs: cyclin dependent 
kinases; ELISA: enzyme-linked immunosorbent assay; MSF assay: malaria SYBR 
Green I fluorescence assay; RCN: Relative Copy Number; MTS: 3-(4,5-dimeth-
ylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; 
DAPI: 4′,6-diamidino-2-phenylindole. hDHFR: human dihydrofolate reductase; 
IC50: 50 % growth-inhibitory concentration; PfDHFR-TS: P. falciparum bifunc-
tional dihydrofolate reductase-thymidylate synthase enzyme; EdU: 5-ethynyl-
2′-deoxyuridine; h: hours.
Acknowledgements
I am grateful to Lynne Harris and James Edwards-Smallbone for culturing 
some of the TK-expressing parasite lines; to Srabasti Chakravorty for advice 
and the loan of reagents for ELISA; to Divya Chari, Alinda Fernandes and Dave 
Furness for access to microscopy; to Mirna Maarabouni for advice and loan 
of reagents for the MTS assay; and to Paul Horrocks for critical reading of the 
manuscript. CJM is supported in part by UK Research Council grants MR/
K000535/1 and BB/K009206/1.
Competing interests
The author declares that she has no competing interests.
Received: 8 September 2015   Accepted: 24 November 2015
References
 1. WHO: World Malaria Report 2014. Geneva, World Health Organization, 
2014.
 2. Arnot DE, Gull K. The Plasmodium cell-cycle: facts and questions. Ann 
Trop Med Parasitol. 1998;92:361–5.
 3. Arnot DE, Ronander E, Bengtsson DC. The progression of the intra-
erythrocytic cell cycle of Plasmodium falciparum and the role of the 
centriolar plaques in asynchronous mitotic division during schizogony. 
Int J Parasitol. 2011;41:71–80.
 4. Gerald N, Mahajan B, Kumar S. Mitosis in the human malaria parasite 
Plasmodium falciparum. Eukaryot Cell. 2011;10:474–82.
 5. Doerig C, Endicott J, Chakrabarti D. Cyclin-dependent kinase homo-
logues of Plasmodium falciparum. Int J Parasitol. 2002;32:1575–85.
 6. Doerig C, Billker O, Haystead T, Sharma P, Tobin AB, Waters NC. Protein 
kinases of malaria parasites: an update. Trends Parasitol. 2008;24:570–7.
 7. Naughton JA, Bell A. Studies on cell-cycle synchronization in the 
asexual erythrocytic stages of Plasmodium falciparum. Parasitology. 
2007;134:331–7.
Additional file
Additional file 1. Controls demonstrate that BrdU sensitivity of TK-
expressing parasites is not artefactual. A. qPCR data showing the average 
copy number of the TK gene in 3 different +TK parasite lines: +TK and 
+TK(B) shown in Fig. 3, and +TK(int) shown in Additional file 1C. Relative 
copy number is calculated relative to two single-copy housekeeping 
genes encoding seryl-tRNA synthetase and actin. Error bars show stand-
ard deviation of triplicate readings. B. MTS assay on the MCF-7 human 
breast cancer cell line, over a range of 1 mM to 3nM BrdU. Error bars show 
standard deviation of triplicate readings. C. MSF assay on the +TK(int) 
parasite line grown in the presence or absence of WR99210, over a range 
of 5 mM to 2.3 nM BrdU. Error bars show standard deviation of triplicate 
readings. IC50 values, calculated with GraphPad Prism software, show that 
there is no difference in the parasites’ sensitivity to BrdU in the presence or 
absence of WR99210. 95% confidence intervals are given in parentheses.
 8. Inselburg J, Banyal HS. Synthesis of DNA during the asexual cycle of 
Plasmodium falciparum in culture. Mol Biochem Parasitol. 1984;10:79–87.
 9. Dimitrova DS, Gilbert DM. Temporally coordinated assembly and disas-
sembly of replication factories in the absence of DNA synthesis. Nat Cell 
Biol. 2000;2:686–94.
 10. Doi H, Ishii A, Shimono K. A rapid in vitro assay system using anti-bromo-
deoxyuridine for drug susceptibility of Plasmodium falciparum. Trans R 
Soc Trop Med Hyg. 1988;82:190–3.
 11. Biswas S, Valecha N. Bromo-deoxyuridine based assay for detection of 
parasite and drug sensitivity in Plasmodium falciparum in vitro. Indian J 
Exp Biol. 1996;34:1237–40.
 12. Adovelande J, Boulard Y, Berry JP, Galle P, Slodzian G, Schrevel J. Detec-
tion and cartography of the fluorinated antimalarial drug mefloquine in 
normal and Plasmodium falciparum infected red blood cells by scanning 
ion microscopy and mass spectrometry. Biol Cell. 1994;81:185–92.
 13. Janse CJ, van Dijk M, Raap AK, Mons B. Bromo-deoxyuridine is not 
incorporated into DNA of malaria parasites. Trans R Soc Trop Med Hyg. 
1991;85:727–8.
 14. Konigk E. Salvage syntheses and their relationship to nucleic acid 
metabolism. Bull World Health Organ. 1977;55:249–52.
 15. Krungkrai J, Yuthavong Y, Webster HK. High-performance liquid chro-
matographic assay for thymidylate synthase from the human malaria 
parasite, Plasmodium falciparum. J Chromatogr. 1989;487:51–9.
 16. Sherman IW. Transport of amino acids and nucleic acid precursors in 
malarial parasites. Bull World Health Organ. 1977;55:211–25.
 17. Gutteridge WE, Trigg PI. Incorporation of radioactive precursors into DNA 
and RNA of Plasmodium knowlesi in vitro. J Protozool. 1970;17:89–96.
 18. Reyes P, Rathod PK, Sanchez DJ, Mrema JE, Rieckmann KH, Heidrich HG. 
Enzymes of purine and pyrimidine metabolism from the human malaria 
parasite, Plasmodium falciparum. Mol Biochem Parasitol. 1982;5:275–90.
 19. Upston JM, Gero AM. Parasite-induced permeation of nucleosides in 
Plasmodium falciparum malaria. Biochim Biophys Acta. 1995;1236:249–58.
 20. Rager N, Mamoun CB, Carter NS, Goldberg DE, Ullman B. Localization of 
the Plasmodium falciparum PfNT1 nucleoside transporter to the parasite 
plasma membrane. J Biol Chem. 2001;276:41095–9.
 21. Desai SA, Krogstad DJ, McCleskey EW. A nutrient-permeable channel on 
the intraerythrocytic malaria parasite. Nature. 1993;362:643–6.
 22. Gero AM, Wood AM, Hogue DL, Upston JM. Effect of diamide on nucleo-
side and glucose transport in Plasmodium falciparum and Babesia bovis 
infected erythrocytes. Mol Biochem Parasitol. 1991;44:195–206.
 23. Downie MJ, Saliba KJ, Howitt SM, Broer S, Kirk K. Transport of nucleosides 
across the Plasmodium falciparum parasite plasma membrane has char-
acteristics of PfENT1. Mol Microbiol. 2006;60:738–48.
 24. Lauer SA, Rathod PK, Ghori N, Haldar K. A membrane network for 
nutrient import in red cells infected with the malaria parasite. Science. 
1997;276:1122–5.
 25. Haldar K, Samuel BU, Mohandas N, Harrison T, Hiller NL. Transport mecha-
nisms in Plasmodium-infected erythrocytes: lipid rafts and a tubovesicu-
lar network. Int J Parasitol. 2001;31:1393–401.
 26. Lengronne A, Pasero P, Bensimon A, Schwob E. Monitoring S phase 
progression globally and locally using BrdU incorporation in TK(+) yeast 
strains. Nucleic Acids Res. 2001;29:1433–42.
 27. Duraisingh MT, Triglia T, Cowman AF. Negative selection of Plasmodium 
falciparum reveals targeted gene deletion by double crossover recombi-
nation. Int J Parasitol. 2002;32:81–9.
 28. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M. Simple and 
inexpensive fluorescence-based technique for high-throughput antima-
larial drug screening. Antimicrob Agents Chemother. 2004;48:1803–6.
 29. Trager W, Jenson JB. Cultivation of malarial parasites. Nature. 1978;273:621–2.
 30. Lambros C, Vanderberg JP. Synchronization of Plasmodium falciparum 
erythrocytic stages in culture. J Parasitol. 1979;65:418–20.
 31. Dluzewski AR, Ling IT, Rangachari K, Bates PA, Wilson RJ. A simple method 
for isolating viable mature parasites of Plasmodium falciparum from 
cultures. Trans R Soc Trop Med Hyg. 1984;78:622–4.
 32. Fidock DA, Wellems TE. Transformation with human dihydrofolate 
reductase renders malaria parasites insensitive to WR99210 but does 
not affect the intrinsic activity of proguanil. Proc Natl Acad Sci USA. 
1997;94:10931–6.
 33. Dzikowski R, Frank M, Deitsch K. Mutually exclusive expression of viru-
lence genes by malaria parasites is regulated independently of antigen 
production. PLoS Pathog. 2006;2:e22.
Page 12 of 12Merrick  Malar J  (2015) 14:490 
 34. Ginsburg H. Malaria Parasite Metabolic Pathways [WWW document] URL 
http://mpmp.huji.ac.il/. 2015.
 35. Hasenkamp S, Sidaway A, Devine O, Roye R, Horrocks P. Evaluation of 
bioluminescence-based assays of anti-malarial drug activity. Malar J. 
2013;12:58.
 36. Kiel MJ, He S, Ashkenazi R, Gentry SN, Teta M, Kushner JA, et al. Haema-
topoietic stem cells do not asymmetrically segregate chromosomes or 
retain BrdU. Nature. 2007;449:238–42.
 37. Greer S. Studies on ultraviolet irradiation of Escherichia coli containing 
5-bromouracil in its DNA. J Gen Microbiol. 1960;22:618–34.
 38. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, et al. 
Genome sequence of the human malaria parasite Plasmodium falcipa-
rum. Nature. 2002;419:498–511.
 39. Eichinger L, Pachebat JA, Glockner G, Rajandream MA, Sucgang R, 
Berriman M, et al. The genome of the social amoeba Dictyostelium 
discoideum. Nature. 2005;435:43–57.
 40. Guespin-Michel JF, Menahem M, Monier F, Felenbok B. Kinetic of 
5-bromodeoxyuridine action on Dictyostelium discoideum growth and 
development. Exp Cell Res. 1976;98:184–90.
 41. Felenbok B, Monier F, Guespin-Michel JF. Effect of the thymidine ana-
logue 5-bromo-2′-deoxyuridine on Dictyostelium discoideum develop-
ment. Cell Differ. 1974;3:55–62.
 42. Podgorski G, Deering RA. Thymidine-requiring mutants of Dictyostelium 
discoideum. Mol Cell Biol. 1984;4:2784–91.
 43. Krefft M, Weijer CJ. Expression of a cell surface antigen in Dictyostelium 
discoideum in relation to the cell cycle. J Cell Sci. 1989;93:199–204.
 44. Choi SW, Keyes MK, Horrocks P. LC/ESI-MS demonstrates the absence of 
5-methyl-2′-deoxycytosine in Plasmodium falciparum genomic DNA. Mol 
Biochem Parasitol. 2006;150:350–2.
 45. Ponts N, Fu L, Harris EY, Zhang J, Chung DW, Cervantes MC, et al. 
Genome-wide mapping of DNA methylation in the human malaria 
parasite Plasmodium falciparum. Cell Host Microbe. 2013;14:696–706.
 46. Masterson JC, O’Dea S. 5-Bromo-2-deoxyuridine activates DNA damage 
signalling responses and induces a senescence-like phenotype in p16-
null lung cancer cells. Anticancer Drugs. 2007;18:1053–68.
 47. Janse CJ, Van der Klooster PF, Van der Kaay HJ, Van der Ploeg M, Over-
dulve JP. Rapid repeated DNA replication during microgametogenesis 
and DNA synthesis in young zygotes of Plasmodium berghei. Trans R Soc 
Trop Med Hyg. 1986;80:154–7.
 48. Malinsky J, Koberna K, Stanek D, Masata M, Votruba I, Raska I. The supply 
of exogenous deoxyribonucleotides accelerates the speed of the replica-
tion fork in early S-phase. J Cell Sci. 2001;114:747–50.
 49. Hott A, Casandra D, Sparks KN, Morton LC, Castanares GG, Rutter A, Kyle 
DE. Artemisinin-resistant Plasmodium falciparum parasites exhibit altered 
patterns of development in infected erythrocytes. Antimicrob Agents 
Chemother. 2015;59:3156–67.
 50. Wassmer SC, Taylor TE, Rathod PK, Mishra SK, Mohanty S, Arevalo-
Herrera M, et al. Investigating the pathogenesis of severe malaria: a 
multidisciplinary and cross-geographical approach. Am J Trop Med Hyg. 
2015;93:42–56.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
